Recurrence of premature rupture of membranes among pregnancies admitted to a Tertiary Hospital: a retrospective cohort study.

PURPOSE: The recurrence of PPROM (Preterm Premature Rupture of Membranes) has multifactorial etiology. The aim of this study is to discuss outcome measures of subsequent PPROMs after pregnancy with PPROM before 37 weeks 'gestation. METHOD: One hundred fifty-one patients were identified with PPROM between 20 + 0- 36 + 6 weeks of gestation between 2012 and 2017 in Trakya University Hospital. The subsequent pregnancy (n = 68) outcomes were retrospectively analyzed. RESULTS: The rate of PPROMs among all deliveries was 4.7%. The recurrence rate of PPROM in the next pregnancies was 13.2%. No differences in smoking, comorbidity, latency, antibiotic use, levels of leucocytes and C-Reactive Protein were observed between women with PPROM and without PPROM in previous and subsequent pregnancies. The interpregnancy intervals in subsequent pregnancies with PPROM were significantly longer than those without PPROM (p = 0.015). The subsequent pregnancies without PPROM had longer gestational weeks of PPROM and birth according to previous pregnancies (p = 0.049; p = 0.014). CONCLUSION: The short interpregnancy interval may be considered in the planning of pregnancies of these women who had previous PPROM.

Surgical management of stage-2 medication-related osteonecrosis of the jaw with transplantation of human amniotic membrane: Preliminary results.

Medication-related osteonecrosis of the jaw (MRONJ) is a drug adverse reaction. Seven osteonecrosis areas in 5 cases were treated with stage-2 MRONJ using human amniotic membrane (HAM) transplantation after sequestrectomy. Patients were evaluated in terms of infection (pain, erythema, and pus), mucosal coverage, and pain at 1, 2, 4, 8, and 12 weeks. Patients who showed improvement (total mucosal coverage, no sign of infection and pain) at the end of 12 weeks were followed up every 8 weeks. Also, radiographic examinations (panoramic radiography at every 8 weeks, cone-beam computed tomography at every 6 months) were performed to evaluate bone destruction. Complete mucosal closure was achieved in 6 necrosis sites. In only 1 patient, mucosal coverage was not achieved. No pain and infection relapse were observed during the follow-ups. HAM might be an effective material in terms of soft tissue healing and elimination of pain and infection for stage-2 MRONJ. Clinical Trials Registration Number: NCT04967963.